Segment Information (Tables)

12 Months Ended

Jun. 30, 2012

Schedule of Segment Perfomance Measures

The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis.

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated  Totals
2012
Net sales	$	105,249	$	162,998	$	176,141	$	-		$	444,388
Gross profit		29,932		25,472		26,628		-			82,032
Income before income taxes		11,683		8,066		10,570		(5,579	)		24,740
2011
Net sales	$	69,856	$	149,340	$	193,232	$	-		$	412,428
Gross profit		15,534		23,897		26,407		-			65,838
Income before income taxes		2,898		7,294		10,198		(3,428	)		16,962
2010
Net sales	$	47,046	$	136,454	$	163,131	$	-		$	346,631
Gross profit		7,780		22,071		24,304		-			54,155
Income before income taxes		982		4,657		8,229		(3,665	)		10,203

Schedule of Net Sales and Gross Profit by Source Country

Net sales and gross profit by source country for the years ended June 30, 2012, 2011 and 2010 were as follows:

	Net Sales						Gross Profit
	2012		2011		2010		2012		2011		2010
United States	$	289,630	$	260,686	$	216,687	$	58,733	$	42,472	$	33,139
Germany		82,600		78,044		68,121		14,303		14,353		13,038
Netherlands		13,738		15,451		14,377		1,706		1,712		1,894
France		33,143		32,718		24,553		3,885		3,560		2,585
Asia-Pacific		25,277		25,529		22,893		3,405		3,741		3,499
Total	$	444,388	$	412,428	$	346,631	$	82,032	$	65,838	$	54,155

Schedule of Long-Lived Assets by Geographic Region

Long-lived assets by geographic region as of June 30, 2012 and June 30, 2011 were as follows:

	Long-lived assets
	2012		2011
United States	$	85,650	$	90,955
Europe		2,388		2,779
Asia-Pacific		2,413		2,644
Total	$	90,451	$	96,378